Clinical trials: Type II Diabetes Mellitus
Diabetes Mellitus, Type 2
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
The primary objective of this study is to evaluate the effectiveness of HRS9531 compared to placebo in controlling blood glucose levels after 36 weeks of treatment
- Trial name
- NCT06650007
- Testing
- HRS9531 Injection
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers.
- Trial name
- NCT07304700
- Testing
- CKD-383 0.5/10/1000mg, CKD-501, D744, D150
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity, Overweight
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06993792
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
The primary objective of this trial is to evaluate the safety and tolerability of multiple intravenous doses of NOX-E36 in healthy subjects and patients with type 2 diabetes mellitus.
- Trial name
- NCT01085292
- Testing
- NOX-E36
- Where
- 5 sites in Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- TME Pharma AG
Type 2 Diabetes Mellitus
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
A Clinical trial to investigate the pharmacokinetic drug interaction and safety of CKD-501, D759 and D150
- Trial name
- NCT04431687
- Testing
- CKD 501, D759, D150, CKD-501, D759, D150
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Feasibility Study of Blood Glucose Monitoring With the Non-invasive Medical Device D-Base
This study aims to evaluate the feasibility of monitoring the blood glucose values by measuring the glucose in the interstitial fluid of the skin on the wrist of subjects with diabetes mellitus type 1 and 2.
- Trial name
- NCT05169034
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Diamontech AG
Diabetes Mellitus, Type 2
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to identify and evaluate the event rate of the composite endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for participants with Type 2 Diabetes mellitus (T2DM) and…
- Trial name
- NCT03249506
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 25,358 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes
The study subjects will be separated into 2 groups, depending on their previous insulin therapy with approximately 50% of subjects from each group, continuous glucose monitoring (CGM) naive.
- Trial name
- NCT04617795
- Testing
- Omnipod 5 Automated Insulin Delivery System
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Insulet Corporation
Type 2 Diabetes Mellitus
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00127192
- Testing
- sitagliptin phosphate
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the clinical efficacy and safety of SK-0403 in patients with Type2 Diabetes Mellitus
- Trial name
- NCT00532506
- Testing
- SK-0403
- Where
- 10 sites in Japan
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.
- Trial name
- NCT01301833
- Testing
- teneligliptin, glinide, biguanide
- Where
- Japan
- Volunteers
- 462 people
- Sponsor
- Tanabe Pharma Corporation
Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a…
- Trial name
- NCT06603571
- Testing
- LY3841136, Tirzepatide
- Where
- 52 sites in United States, Argentina
- Volunteers
- 367 people
- Sponsor
- Eli Lilly and Company
Uncontrolled Type 2 Diabetes Mellitus
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in…
- Trial name
- NCT04801199
- Testing
- CPL-2009-0031 140 mg, Sitagliptin 100mg
- Where
- 12 sites in India
- Volunteers
- 355 people
- Sponsor
- Cadila Pharnmaceuticals
Diabetes, Diabetes Mellitus, Type 1
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles
This trial is conducted in Europe. The primary aim of this clinical trial is to locate and compare simulated insulin injections (injections of sterile atmospheric air) in normal weight and obese patients with diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00871416
- Testing
- NovoFine® needle 6 mm, NovoFine® needle 12 mm
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes.
- Trial name
- NCT01029704
- Testing
- EGT0001442
- Where
- 12 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Theracos
Diabetes, Diabetes Mellitus, Type 1
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
This study is conducted in Asia. The aim of this observational study is to evaluate the side effects profile and benefits of using intravenous insulin aspart infusion in hospitalised subjects under normal clinical practice…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00700648
- Testing
- insulin aspart
- Where
- India
- Volunteers
- 3,024 people
- Sponsor
- Novo Nordisk A/S
Weight Loss, Metabolic Syndrome
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes.
- Conditions
- Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
- Trial name
- NCT05874635
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Type 1 Diabetes, Type 2 Diabetes
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Trial name
- NCT05893797
- Testing
- Insulin Lispro, Tempo Smart Button, Dexcom G6 CGM
- Where
- 9 sites in France
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.